Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam

An evaluation of three new rapid diagnostic test kits for human immunodeficiency virus types 1 and 2 (HIV-1/2), hepatitis B surface antigen (HBsAg), and syphilis involved a two-phase comparison of rapid diagnostic assays using prospectively collected from hospitals and clinics in Ho Chi Minh City, Vietnam. After specificity and sensitivity testing, three new rapid diagnostic test kits were tested in parallel with six commonly used diagnostic test kits. The Determine(TM) HIV-1/2 test had fewer indeterminate or equivocal results than the Capillus(R) HIV-1/HIV-2 or HIV Blot 2.2(TM) tests. However, the Determine(TM) HIV-1/2 test yielded one false-positive result when compared with the Serodia(R) HIV, HIV Blot 2.2(TM), and microparticle enzyme immunoassay (IMx(R)) HIV tests. The Serodia(R) HBsAg test yielded more false-negative results when compared with the Determine(TM) HBsAg diagnostic test kit. The results of the syphilis diagnostic tests evaluated in this clinical trial consistently agreed with those of the rapid plasma reagin test for syphilis. The Determine(TM) Syphilis Treponema pallidum (TP) test had three false-positive results compared with the Serodia(R) TP and the Serodia(R) TP.particle agglutination (PA) tests, which had two false-positive results that were confirmed as negative by an ELISA. Application of these serologic tests within this comparative evaluation framework, using the World Health Organization alternative testing strategies, proved to be an effective way to determine serostatus related to HIV, hepatitis B, and syphilis.